Migraine Pipeline Review, H2 2020: Therapeutics Development & Assessment, Drug Profiles, Dormant Projects, Discontinued Products, Development Milestones, Competitive Landscape
Dublin, Dec. 23, 2020 (GLOBE NEWSWIRE) -- The "Migraine - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Migraine - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 8, 18, 12, 1, 32, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.
Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Introduction
Migraine - Overview
Migraine - Therapeutics Development
Migraine - Therapeutics Assessment
Migraine - Companies Involved in Therapeutics Development
Migraine - Drug Profiles
Migraine - Dormant Projects
Migraine - Discontinued Products
Migraine - Product Development Milestones
Appendix
Companies Mentioned
4P Therapeutics LLC
Acadia Pharmaceuticals Inc
Achelios Therapeutics Inc
Acorda Therapeutics Inc
AgoneX Biopharmaceuticals Inc
Allergan Ltd
Allodynic Therapeutics LLC
Amgen Inc
AOBiome LLC
Aptarion biotech AG
Asarina Pharma AB
Assertio Therapeutics Inc
Astrocyte Pharmaceuticals Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Better Life Pharmaceuticals Inc
Biogen Inc
Biohaven Pharmaceutical Holding Company Ltd
Blackthorn Therapeutics Inc
Cerecin Inc
Charleston Laboratories Inc
Citragen Pharmaceuticals Inc
Corium Inc
Crossject SA
Curatis AG
CURx Pharmaceuticals Inc
DelNova Inc
Eli Lilly and Co
Epalex Corp
Exxel Pharma Inc
H. Lundbeck AS
Impel NeuroPharma Inc
InKemia IUCT Group SA
InStar Technologies AS
IntelGenx Corp
Invisio Ltd
Ionis Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Lateral Pharma Pty Ltd
Living Cell Technologies Ltd
MannKind Corp
Medytox Inc
Merck & Co Inc
NAL Pharmaceuticals Ltd
NeurAxon Pharma Inc
NeuroPharm Inc
NutriBand Inc
OWP Pharmaceuticals Inc
Panaxia Pharmaceutical Industries Ltd
Pharmaleads SA
Pharmnovo AB
Pherin Pharmaceuticals Inc
Promius Pharma LLC
Pulmatrix Inc
Qingdao Chia Tai Haier Pharmaceutical Co Ltd
RAFT Pharmaceuticals
Revance Therapeutics Inc
Satsuma Pharmaceuticals Inc
Seurat Therapeutics Inc
Shanghai Junshi Bioscience Co Ltd
Shin Nippon Biomedical Laboratories Ltd
Sorrento Therapeutics Inc
Sosei Heptares
Suda Pharmaceuticals Ltd
Teva Pharmaceutical Industries Ltd
Trevena Inc
Trigemina Inc
TrioxBio Inc
United Neuroscience Ltd
Xenon Pharmaceuticals Inc
Xoc Pharmaceuticals Inc
Zosano Pharma Corp
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/u7s9rp
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900